Tags

Type your tag names separated by a space and hit enter

Probiotic supplementation improves tolerance to Helicobacter pylori eradication therapy--a placebo-controlled, double-blind randomized pilot study.

Abstract

BACKGROUND

H. pylori is the major cause of chronic gastritis, and a risk factor for peptic ulcer and gastric cancer.

AIM

To investigate the effect of probiotic supplementation on the tolerance and efficacy of H. pylori eradication treatment in a randomized, double-blind, placebo-controlled trial.

METHODS

A total of 338 volunteers were screened for H. pylori infection. The eligibility criteria were met by 47 subjects whose H. pylori infection was verified at the outset and re-evaluated after the treatment by the 13C-urea breath test and by enzyme immunoassay serology. The subjects were randomized to receive probiotic therapy (Lactobacillus rhamnosus GG, L. rhamnosusLC705, Bifidobacterium breve Bb99 and Propionibacterium freudenreichii ssp. shermanii JS) or a placebo during H. pylori eradication and for 3 weeks following the treatment, and recorded their daily symptoms in a standardized diary.

RESULTS

When the frequencies of new or aggravated symptoms were evaluated, no significant differences were found between the two groups for individual symptoms. However, the probiotic group showed less treatment-related symptoms as measured by the total symptom score change (P = 0.038) throughout the H. pylori eradication therapy in contrast to the placebo group. The H. pylori eradication rate was non-significantly higher in the group receiving probiotic therapy (91% vs. 79%, P = 0.42). In this group the recovery of probiotic bacteria in the faeces increased significantly (P < 0.001).

CONCLUSIONS

In this pilot study, probiotic supplementation did not diminish significantly the frequency of new or aggravated symptoms during H. pylori eradication. However, our data suggest an improved tolerance to the eradication treatment when total symptom severity was taken into account. Furthermore, the results show that probiotic bacteria are able to survive in the gastrointestinal tract despite the intensive antimicrobial therapy.

Links

  • FREE Publisher Full Text
  • Authors+Show Affiliations

    ,

    Institute of Biomedicine, Pharmacology, University of Helsinki, Helsinki, Finland.

    , , , , , ,

    Source

    Alimentary pharmacology & therapeutics 21:10 2005 May 15 pg 1263-72

    MeSH

    Adult
    Aged
    Anti-Bacterial Agents
    Breath Tests
    Double-Blind Method
    Drug Therapy, Combination
    Feces
    Female
    Gastrointestinal Diseases
    Helicobacter Infections
    Helicobacter pylori
    Humans
    Lactobacillus
    Male
    Middle Aged
    Pilot Projects
    Probiotics
    Propionibacterium

    Pub Type(s)

    Clinical Trial
    Journal Article
    Randomized Controlled Trial
    Research Support, Non-U.S. Gov't

    Language

    eng

    PubMed ID

    15882248

    Citation

    Myllyluoma, E, et al. "Probiotic Supplementation Improves Tolerance to Helicobacter Pylori Eradication Therapy--a Placebo-controlled, Double-blind Randomized Pilot Study." Alimentary Pharmacology & Therapeutics, vol. 21, no. 10, 2005, pp. 1263-72.
    Myllyluoma E, Veijola L, Ahlroos T, et al. Probiotic supplementation improves tolerance to Helicobacter pylori eradication therapy--a placebo-controlled, double-blind randomized pilot study. Aliment Pharmacol Ther. 2005;21(10):1263-72.
    Myllyluoma, E., Veijola, L., Ahlroos, T., Tynkkynen, S., Kankuri, E., Vapaatalo, H., ... Korpela, R. (2005). Probiotic supplementation improves tolerance to Helicobacter pylori eradication therapy--a placebo-controlled, double-blind randomized pilot study. Alimentary Pharmacology & Therapeutics, 21(10), pp. 1263-72.
    Myllyluoma E, et al. Probiotic Supplementation Improves Tolerance to Helicobacter Pylori Eradication Therapy--a Placebo-controlled, Double-blind Randomized Pilot Study. Aliment Pharmacol Ther. 2005 May 15;21(10):1263-72. PubMed PMID: 15882248.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Probiotic supplementation improves tolerance to Helicobacter pylori eradication therapy--a placebo-controlled, double-blind randomized pilot study. AU - Myllyluoma,E, AU - Veijola,L, AU - Ahlroos,T, AU - Tynkkynen,S, AU - Kankuri,E, AU - Vapaatalo,H, AU - Rautelin,H, AU - Korpela,R, PY - 2005/5/11/pubmed PY - 2005/8/17/medline PY - 2005/5/11/entrez SP - 1263 EP - 72 JF - Alimentary pharmacology & therapeutics JO - Aliment. Pharmacol. Ther. VL - 21 IS - 10 N2 - BACKGROUND: H. pylori is the major cause of chronic gastritis, and a risk factor for peptic ulcer and gastric cancer. AIM: To investigate the effect of probiotic supplementation on the tolerance and efficacy of H. pylori eradication treatment in a randomized, double-blind, placebo-controlled trial. METHODS: A total of 338 volunteers were screened for H. pylori infection. The eligibility criteria were met by 47 subjects whose H. pylori infection was verified at the outset and re-evaluated after the treatment by the 13C-urea breath test and by enzyme immunoassay serology. The subjects were randomized to receive probiotic therapy (Lactobacillus rhamnosus GG, L. rhamnosusLC705, Bifidobacterium breve Bb99 and Propionibacterium freudenreichii ssp. shermanii JS) or a placebo during H. pylori eradication and for 3 weeks following the treatment, and recorded their daily symptoms in a standardized diary. RESULTS: When the frequencies of new or aggravated symptoms were evaluated, no significant differences were found between the two groups for individual symptoms. However, the probiotic group showed less treatment-related symptoms as measured by the total symptom score change (P = 0.038) throughout the H. pylori eradication therapy in contrast to the placebo group. The H. pylori eradication rate was non-significantly higher in the group receiving probiotic therapy (91% vs. 79%, P = 0.42). In this group the recovery of probiotic bacteria in the faeces increased significantly (P < 0.001). CONCLUSIONS: In this pilot study, probiotic supplementation did not diminish significantly the frequency of new or aggravated symptoms during H. pylori eradication. However, our data suggest an improved tolerance to the eradication treatment when total symptom severity was taken into account. Furthermore, the results show that probiotic bacteria are able to survive in the gastrointestinal tract despite the intensive antimicrobial therapy. SN - 0269-2813 UR - https://www.unboundmedicine.com/medline/citation/15882248/Probiotic_supplementation_improves_tolerance_to_Helicobacter_pylori_eradication_therapy__a_placebo_controlled_double_blind_randomized_pilot_study_ L2 - https://doi.org/10.1111/j.1365-2036.2005.02448.x DB - PRIME DP - Unbound Medicine ER -